Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07227324

Cannabis Use Registry to Improve Overall Understanding of Symptoms (CURIOUS)

Through partnership with Ontracka, the HealthPartners Institute Cancer Research Center created a secure and compliant app-based technology with the ability to seamlessly collect patient-level data on symptoms, cannabis use, real-time response to cannabis consumption, and patient-reported changes in supportive care medications such as opioids and antiemetics. By joining this registry, patients will have access to expert cannabis education, dosing recommendations, and easy symptom tracking. Patients with cancer and their oncology clinicians can utilize this reliable, cancer-specific data to help them make informed decisions together about how cannabis could be incorporated into a treatment plan. To learn more and sign up, visit https://study.ontracka.com/cannabiscurious

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

HealthPartners Institute Cancer Research Center

Saint Louis Park, Minnesota, 55426, United States

Location status: Recruiting

Location contact

Dylan Zylla, MD, MS

PRINCIPAL_INVESTIGATOR

Jordan Cowger, Project Manager, MPH

CONTACT

[email protected]

952-993-6071

About this study

The CURIOUS project enhances the ability to seamlessly collect patient-level data on symptoms, cannabis use, real-time response to cannabis consumption, and patient-reported changes in supportive care medications such as opioids and antiemetics. Any patient interested in cannabis use can access the weblink to receive information about the CURIOUS study. An electronic version of the informed consent document will be available for them to review.

Patients interested in participating in the CURIOUS study will sign an electronic consent form on the app that describes how data will be used and stored by the HealthPartners and the Ontracka teams. They will be required to submit their name, email, and date of birth. This will automatically establish an account in the OnTracka platform and provide instruction on how to download and install the OnTracka mobile app. After patients consent to participate, they will receive access to the Ontracka app to track cannabis consumption and symptom responses as well as complete embedded validated questionnaires sent to them through the app at defined intervals; NCI PRO-CTCAE (PRO) (every other week), PROMIS Global (QOL) (every 4 weeks) and medication logs (every 4 weeks) through 12 weeks. After week 12 collection, they will complete all surveys once again in month 6 and month 12.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • any adult aged 18 or older who is diagnosed with cancer and using cannabis

Treatment and study plan

Primary outcomes

  1. Adherence

    Time frame: from enrollment to the first 90 days of study participation

    Assess adherence to CURIOUS platform by determining the percentage of consented patients who access the app/survey at least once per month during the first 90 days.

Study contacts

Contact information is provided by the study sponsor or research team.

Jordan Cowger, MPH

CONTACT

[email protected]

952-993-6071

Sponsors and collaborators

Lead sponsor

HealthPartners Institute

Other

Collaborators

  • Ontracka

Registry information

Acronym: CURIOUS

Important dates

Study start
2025
Primary completion
2027
Study completion
2028
First posted
Nov 12, 2025
Registry last updated
Nov 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.